Bright Minds Biosciences Inc. (DRUG)

NCM – Цена в реальном времени. Валюта: USD

65.79

+2.15 (3.38%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

65.63

-0.16 (-0.24%)

После закрытия: Jun 26, 2026, 6:58 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Bright Minds Biosciences Inc. (DRUG)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Bright Minds Biosciences Inc. (DRUG)

Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference

Bright Minds Biosciences to Present at Upcoming Conferences

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday

Видео

No Data

Пресс-релизы

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

Search stocks

Bright Minds Biosciences Inc. (DRUG)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Bright Minds Biosciences Inc. (DRUG)

Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference

Bright Minds Biosciences to Present at Upcoming Conferences

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday

Видео

No Data

Пресс-релизы

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)